1. Home
  2. CNM vs IMVT Comparison

CNM vs IMVT Comparison

Compare CNM & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Core & Main Inc.

CNM

Core & Main Inc.

HOLD

Current Price

$43.01

Market Cap

7.9B

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$37.29

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNM
IMVT
Founded
1996
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Durable Goods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9B
8.5B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
CNM
IMVT
Price
$43.01
$37.29
Analyst Decision
Buy
Buy
Analyst Count
11
8
Target Price
$61.55
$33.00
AVG Volume (30 Days)
2.6M
1.1M
Earning Date
06-09-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
8.45
N/A
EPS
1.34
N/A
Revenue
$7,647,000,000.00
N/A
Revenue This Year
$4.89
N/A
Revenue Next Year
$4.21
N/A
P/E Ratio
$32.13
N/A
Revenue Growth
2.77
N/A
52 Week Low
$40.03
$15.00
52 Week High
$59.66
$45.42

Technical Indicators

Market Signals
Indicator
CNM
IMVT
Relative Strength Index (RSI) 51.74 40.11
Support Level $42.19 $37.16
Resistance Level $44.75 $41.22
Average True Range (ATR) 1.33 1.24
MACD 0.20 -0.22
Stochastic Oscillator 74.15 29.00

Price Performance

Historical Comparison
CNM
IMVT

About CNM Core & Main Inc.

Core & Main is a leading specialty distributor with a focus on water, wastewater, storm drainage, and fire protection products. The company provides solutions to municipalities, private water companies, and professional contractors across municipal, nonresidential, and residential end markets. The company's specialty products and services are used in the maintenance, repair, replacement, and construction of water and fire protection infrastructure.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: